Results 61 to 70 of about 885,175 (334)

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Clinical Cancer Research, 2017
Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced-stage metastatic melanoma, as well as patients with many other solid cancers, yielding long-lasting responses and improved survival.
T. N. Gide, J. Wilmott, R. Scolyer, G. Long   +3 more
semanticscholar   +1 more source

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.

Journal of Clinical Oncology, 2020
PURPOSE Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options. Studies of single-agent immunotherapy regimens have shown minimal benefit.
M. Pelster, S. Gruschkus, R. Bassett, D. Gombos, M. Shephard, L. Posada, Maura S Glover, Rinata Simien, A. Diab, P. Hwu, B. Carter, S. Patel   +11 more
semanticscholar   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock

Case Reports in Oncology, 2020
Since the cost of molecular biological methods for Spitzoid neoplasms is expensive, the number of institutes that employ these methods might be limited. Preferentially expressed antigen in melanoma (PRAME) is a tumor-associated antigen that is useful to ...
Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Akira Hashimoto, Setsuya Aiba   +6 more
doaj   +1 more source

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Journal of Clinical Oncology, 2017
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited on potential predictors of CR and patient disposition after pembrolizumab discontinuation after ...
C. Robert, A. Ribas, O. Hamid, A. Daud, J. Wolchok, A. Joshua, W. Hwu, J. Weber, T. Gangadhar, R. Joseph, R. Dronca, A. Patnaik, H. Zarour, R. Kefford, P. Hersey, Jin Zhang, James R. Anderson, Scott J. Diede, S. Ebbinghaus, F. Hodi   +19 more
semanticscholar   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics

Cells
We aimed to review the molecular characteristics of metastatic melanoma and the role of surgery in metastasectomy for metastatic melanoma. We performed a systematic literature search on PubMed to identify relevant studies focusing on several mutations ...
Kulkaew Sukniam, Harsheen K. Manaise, Kyle Popp, Reed Popp, Emmanuel Gabriel   +4 more
doaj   +1 more source

Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review

Chinese Journal of Cancer, 2017
Metastatic melanoma has long been considered to have a very poor prognosis and to be chemo-resistant. However, a subgroup of patients with metastatic melanoma presents remarkable responses to chemotherapeutic agents, even in the absence of a response to ...
Aurélien Simon, Hampig Raphael Kourie, Joseph Kerger   +2 more
doaj   +1 more source

Blood‐Lymphatic Integrated System with Heterogeneous Melanoma Spheroids via In‐Bath Three‐Dimensional Bioprinting for Modelling of Combinational Targeted Therapy

Advanced Science, 2022
Although metastatic melanoma can be managed with chemotherapy, its heterogeneity and resistance to therapy remain poorly understood. In addition to the spread of melanoma in the bloodstream, melanoma‐stroma interaction and the lymphatic system play ...
Won‐Woo Cho, Minjun Ahn, Byoung Soo Kim, Dong‐Woo Cho   +3 more
doaj   +1 more source